Clinical Trial Update: St. John's Wort Extract LI 160 for the Treatment of Atypical Depression [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating St. John's Wort extract LI 160 for atypical depression has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Depression

Drugs mentioned

• St. John's Wort Extract LI 160 (Hypericum perforatum extract LI 160)

Snippet

Sponsor: Cassella-med GmbH & Co. KG | Conditions: Atypical Depression | Phase 3 | Status: COMPLETED